Difference between revisions of "Motesanib (AMG-706)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "2 PubMed]" to "2/ PubMed]") |
Warner-admin (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' AMG 706 | + | *'''Code name:''' AMG-706 |
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 12:30, 27 July 2023
Mechanism of action
From the NCI Drug Dictionary: The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors
Preliminary data
Thyroid cancer
- Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. link to original article PubMed
Also known as
- Code name: AMG-706